Primary screening for HPV provides 60% to 70% greater protection against invasive cervical cancer than the cytology-based (smear test) screening currently used.
Women vaccinated with one dose of a HPV vaccine had antibodies against the viruses that remained stable in their blood for 4 years, suggesting that a single dose of vaccine may be sufficient to generate long-term immune responses against new HPV infections, and ultimately cervical cancer.
Follow-up of four trials shows HPV screening more efficacious for preventing invasive cervical carcinoma.
Brachytherapy treatment was found to be associated with better cause-specific survival and overall survival in women with cervical cancer in a new study.
or women with stage IIIB squamous cervical cancer, cisplatin added to radiotherapy plus high-dose-rate brachytherapy (HDRB) is associated with improved disease-free survival.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|